)
Our Patients
Our Promise to Patients: You Come First
Welcome home
You've likely had a long journey, but now you're among friends. We understand rare and serious conditions because we've specialized in it for decades and we're here to help. By working closely with people like Omar (pictured above), we're able to identify and pursue new innovations that address unmet medical needs. Meanwhile, we continue to enhance our current treatments for conditions, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, hereditary angioedema, and Alpha-1 antitrypsin deficiency.
We are driven by our promise to save lives and improve the quality of life for our patients and their families, because living with a rare disease impacts more than just one person. We offer support programs and activities and we partner with patient advocacy organizations to improve and expand educational and outreach efforts. We also work with government authorities to ensure patients have access to the medicines they need to live life to the fullest.
How can we help you?
Immunodefiency & Autoimmune Diseases
We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Treatments are available for the following conditions:
Within the United States:
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)
Outside the United States:
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Secondary Immunodeficiency
- Kawasaki Disease (KD)
- Guillain-Barré Syndrome (GBS)
Hereditary Bleeding Disorders
We are a world leader in innovative medicines for the treatment of bleeding disorders. We offer the largest portfolio for the treatment of hereditary bleeding disorders with more than a dozen plasma-derived and recombinant coagulation factor concentrates. Treatments are available for the following conditions:
Within the United States:
- Hemophilia A
- Hemophilia B
- von Willebrand Disease
- Factor XIII Deficiency
- Fibrinogen Deficiency
Outside the United States:
- Hemophilia A
- Hemophilia B
- von Willebrand Disease
- Factor XIII Deficiency
- Fibrinogen Deficiency
- Factor X Deficiency
Hereditary Angioedema (HAE)
We recently introduced the world's first subcutaneous preventative treatment for attacks of Hereditary Angioedema (HAE), while still offering our intravenous C1-esterase inhibitor therapy for on-demand treatment.
Alpha 1 Antitrypsin Deficiency
Our Alpha 1 proteinase inhibitor treats Alpha 1 Antitrypsin Deficiency (AATD) in patients with Alpha 1-related emphysema.
Life has changed for the better now. She's full of life and energy.
- Annette Gregory, Mother of Primary Immunodeficiency Patient Baylee
Current Clinical Trials
| Therapeutic Area | Condition | Description | |
| Bleeding Disorders |
Hemophilia A | An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. | Learn More |
| Hemophilia B | A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B | Learn More | |
| Hemophilia A & B | A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of rVIIa-FP (CSL 689) in Subjects With Hemophilia (A or B) and Inhibitors | Learn More | |
| Congenital Fibrinogen Deficiency | An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency | Completed | |
| Von Willebrand | Study of Voncento® in Subjects With Von Willebrand Disease | Completed | |
| Warfarin Reversal | An Observational Study of the Risk of Thromboembolic Events Among Adult Patients Treated With KCENTRA® Compared With Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding | Learn More | |
| Cardiovascular | Acute Coronary Syndrome | Study to investigate CSL112 in Subjects With Acute Coronary Syndrome | Learn More |
| Coronary Heart Disease | Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults | Learn More | |
|---|---|---|---|
| Immunoglobulins | Chronic Inflammatory Demyelinating Polyneuropathy | Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Learn More |
| Primary Immune Deficiency (PID) | Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) | Learn More | |
| Primary Immune Deficiency (PID) | Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules | Completed | |
| Therapeutic Proteins | Other Inflammatory or immune system disorders | Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults | Learn More |
| Transplant | Antibody-mediated kidney transplant rejection | Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients | Learn More |
Participate in a Clinical Trial
Discover what is involved in participating in one of our clinical trials and how you can enroll.
Learn More